According to the 21st Century Business Herald, the reporter learned that Iskra Reic, the new global executive vice president and head of international business of AstraZeneca, issued an internal letter announcing that Lin Xiao will serve as the general manager of AstraZeneca China and Guan Dongmei will serve as the general manager of AstraZeneca China's oncology business. Lin Xiao and Guan Dongmei will become members of the global management team of the biopharmaceutical business unit and the oncology business unit respectively. Lin Xiao, Guan Dongmei, and Hu Yiqing, vice president of AstraZeneca China and head of the rare disease business unit, will all report directly to Iskra Reic, the global executive vice president and head of international business of AstraZeneca. In addition, according to AstraZeneca's disclosure to reporters, Lai Minglong serves as the head of AstraZeneca's global oncology business Dato-DXd and lung cancer business unit, and reports to Mr. Sunil Verma, AstraZeneca's global senior vice president and head of the oncology business unit.